Who Owns MoonLake Immunotherapeutics Stock?
NASDAQ: MLTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 87.90%
- Held by insiders
- 8.62%
- Institutional holders
- 221
- Institutions 87.9%
- Insiders 8.6%
- Public and other 3.5%
Who owns MoonLake Immunotherapeutics stock?
Institutional investors own about 87.9% of MoonLake Immunotherapeutics's shares, spread across 221 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 8.62% of MLTX.
The largest institutional holders are BVF Inc. (18.80%), Deep Track Capital, Lp (8.22%) and T. Rowe Price Investment Management, Inc. (5.03%). Together, the top 10 institutions control 54.1% of shares outstanding. In their latest filings, 8 of the top 10 institutions increased their MLTX positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of MLTX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| BVF Inc. | 16.00M | 18.80% | 0.0% |
| Deep Track Capital, Lp | 7.00M | 8.22% | +9.2% |
| T. Rowe Price Investment Management, Inc. | 4.28M | 5.03% | +100.0% |
| Shaw D.E. & Co., Inc. | 3.37M | 3.95% | +40.8% |
| Cormorant Asset Management, LP | 3.21M | 3.77% | -28.5% |
| Jupiter Topco LLC | 3.09M | 3.63% | +100.0% |
| Logos Global Management LP | 2.67M | 3.14% | +78.3% |
| Weiss Asset Management Lp | 2.58M | 3.03% | +51.1% |
| Citadel Advisors Llc | 1.97M | 2.32% | +49.0% |
| JPMORGAN CHASE & CO | 1.89M | 2.22% | +36.4% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of MLTX
| Fund | Shares | % Held |
|---|---|---|
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 1.61M | 1.90% |
| T. Rowe Price Small-Cap Value Fund, Inc. | 918.59K | 1.08% |
| T. Rowe Price Health Sciences Fund, Inc. | 792.07K | 0.93% |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 605.47K | 0.71% |
| JNL Series Trust-JNL/T. Rowe Price Capital Appreciation Fund | 350.13K | 0.41% |
| T. Rowe Price Exch-Trd Fd.s, Inc.-T Rowe Price Capital Appreciation Eq | 167.77K | 0.20% |
| BlackRock Funds-BlackRock Health Sciences Opportunities Portfolio | 161.39K | 0.19% |
| Voya Investors TRT-VY(R) T. Rowe Price Capital Appreciation PORT. | 160.30K | 0.19% |
| VANGUARD WORLD FUND-Vanguard Health Care Index Fund | 131.91K | 0.15% |
| Exchange Place Advisors Trust-NORTH SQUARE DYNAMIC SMALL CAP FUND | 130.86K | 0.15% |
Frequently asked questions
Who is the largest shareholder of MoonLake Immunotherapeutics?
BVF Inc. is the largest institutional shareholder of MLTX, owning 18.80% of shares outstanding (16.00M shares) as of its latest 13F filing.
What percentage of MoonLake Immunotherapeutics is owned by institutions?
Institutions own about 87.9% of MLTX shares and 96.2% of the public float.
How much of MoonLake Immunotherapeutics do insiders own?
Insiders, such as officers and directors, own about 8.62% of MLTX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.